Affilogic is a private biotech company specialized in discovering and developing Nanofitins®-based therapeutics, through in house programs or collaborations with worldwide industry leaders in the pharmaceutical sector.
Recent news :
Nov 2025 – Affilogic’s CSO presenting latest data on our Orally delivered Nanofitins : Mathieu Cinier is presenting at PEGS EUROPE 2025 latest in-vivo data on our GiJob program.
Aug 2025 – Affilogic’s CEO Presenting latest data generated on our ODC program : Olivier Kitten is presenting at next Immuno-Oncology Summit 2025 latest in-vivo data on our ODC program, showing anti-tumor effect in xenografted mice.
Around the world
CNS Drug Delivery Summit 2025
We are presenting at next CNS Drug Delivery Summit in Boston- USA
Dec 09-11, 2025
PEGS EUROPE 2025
We are presenting at next PEGS Europe in Lisbon – Portugal
Nov 11-13, 2025
TIDES Europe
Come and met us at next TIDES Europe in Basel – Switzerland
Nov 11-13, 2025
Nanofitins
Each Nanofitin® is 20 times smaller than an antibody and demonstrates hyper stability. Their simple protein scaffold is particularly fitted for combination.
Read More
Our Programs
Affilogic develops therapeutic programs leveraging unique Nanofitins’ properties for brain delivery, inhalation of antivirals, oral GI treatments or small size drug conjugates.
Read More
NanoVector
Affilogic works with partners to deliver their therapeutic compounds to specific cells / organs with existing Nanofitins® or through custom generation of Nanofitins®.
Read More